top of page

About NeuCyte 

 

NeuCyte is an early-stage biotechnology company solely focused on neurological diseases. With the expertise on advancing the drug discovery process by using cell based target identification and drug discovery platforms, NeuCyte puts an emphasis on the biology insight of the disorders to develop novel drugs that truly address the altered biological state of the patients.

Our technology accelerates the lead drug identification and optimization process. Our unique human neural platform allows for the evaluation of human specific neural phenotypes that are not identifiable in traditional animal models. This allows for a more reliable predictor of drug efficacy and potential neurotoxicity.

AdobeStock_191185061.jpeg

Our Mission is to improve the lives of those affected by Central Nervous System (CNS) related disorders by developing better translatable solutions to accelerate and optimize CNS drug discovery.   

blue green wave lines.png
NeuCyte Labs.png

As a platform company, NeuCyte has a product and service devision, NeuCyte Laboratories. NeuCyte Labs offers iPSC-derived induced neural cells and drug discovery and nonclinical safety assessment services.

blue green wave lines.png

Leadership Team
 

The NeuCyte staff and scientific advisory board are comprised of some of the top stem cell biologist and neuroscientist in the world. The vast knowledge from our team gives us an unrivaled advantage to address the unmet needs of patients with neurological disorders.

DSC_5061_edited_edited_edited.png

President and

Chief Executive Officer

wayne poon

Head of Neuroscience

DSC_5055_edited.jpg

Senior Director of Drug Discovery

fullsizeoutput_281_edited.jpg

Platform Development Lead

The Flock

Scientific Advisory Board
 

Paul J. Hagerman, MD, PhD

Distinguished Professor in Biochemistry and Molecular Medicine,

University of California at Davis

Pamela Lein, PhD

Department Chair and Professor, Molecular Biosciences, School of Veterinary Medicine

University of California at Davis

Zhiping P. Pang, MD, PhD

Associate Professor of Neuroscience and Cell Biology 

Child Health Institute of New Jersey

Rutgers Robert Wood Johnson Medical School

Julia TCW, PhD

Assistant Professor of Pharmacology and Bioinformatics, 

Director and Principal Investigator, Laboratory of Human Induced Pluripotent Stem Cell Therapeutics

Boston University

Edsel Abud, MD, PhD

KL2 Clinical Scholar at Scripps Translational Institute 

His PhD work helped develop one of the first and most widely used methods to generate microglia cells from iPSCs, showing their functional genomics and role in health and disease.

Why Partner with NeuCyte?
 

NeuCyte has created a proprietary platform based on iPSC technology that enables translatable neuroscience. Solely focusing on neurological disorders, NeuCyte has put together a world-class scientific team of experts for extracting and understanding human disease related phenotypes for target identification.

By harnessing the power of the SynFire® neural cells, our platform allows for in vitro modeling of neurological disorders using disease relevant cells, as well as for phenotypic and target-based drug screens.

AdobeStock_231289239_edited.jpg
Colleagues at Work

Partnership Opportunities 

NeuCyte is open to exploring strategic partnerships to accelerate our current drug discovery programs and to expand the use of our platform beyond our internal R&D programs. We are interested in pursuing other neurological disease models, technologies and drug candidates that are consistent with our core mission of helping those suffering from neurological related illnesses.

For more information, please contact us at enquiries@neucyte.com

bottom of page